Publications by authors named "D Barraco"
Iron therapy in nephropathic patients can allow optimizing treatment with EPO identifying the minimum effective dose capable of improving the patient's quality of life. The most recent studies on iron metabolism and on the interference of iron deficiency syndrome on the performance of some organs, in particular the myocardium, suggest the need to intervene very early, especially in patients with cardiomyopathy and systolic deficit. Setting up an iron therapy in nephropathic patients requires a correct diagnosis.
View Article and Find Full Text PDFLi-S batteries are promising alternatives due to their proven increased gravimetric capacity compared to Li-ion batteries. However, their development is hindered by many technical issues, one of the most challenging being the dissolution and shuttle of polysulfide species, which causes irreversible loss of cathode material leading to rapid capacity fading. Among the possible strategies to mitigate this effect, the choice of suitable solvents is easy to implement and has large room for improvement.
View Article and Find Full Text PDFArticle Synopsis
- Lenalidomide (LEN) can help 60-70% of patients with del(5q) myelodysplastic neoplasm achieve independence from red blood cell transfusions (RBC-TI), but there's a concern about its toxicity and cost.
- The HARMONY Alliance study followed 118 low-intermediate risk MDS patients who discontinued LEN, finding that 50 lost RBC-TI after a median of 49 months.
- Factors like having a low transfusion burden before treatment, completing at least 12 LEN cycles, being younger, and having higher hemoglobin levels at withdrawal were linked to longer RBC-TI duration after discontinuing LEN.
Article Synopsis
- Managing chronic myeloid leukemia (CML) during pregnancy is rare; a study of 87 cases from a registry showed favorable outcomes for most women diagnosed in the chronic phase between 2001-2022.
- Normal childbirth rates were high at 76%, with only 12% of infants being low birth weight, and a low rate of complications was noted regardless of treatment (imatinib or interferon-α).
- About 95% of patients achieved complete hematologic response by labor time, with no disease progression during pregnancy, indicating that specific treatments can be safe for both the mother and baby in later trimesters.